Cellebrite DI
CLBT
Cellebrite DI (CLBT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.02
- EPS estimate
- $0.06
- EPS surprise
- −66.33%
- Revenue surprise
- −0.28%
- Revenue
- $131.1M
- Revenue estimate
- $131.5M
- Reported
- Aug 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | $0.06 | $0.02 | −66.33% | $131.1M | SEC |
| Q1 2026 | May 14, 2026 | $0.05 | $0.04 | −25.65% | $128.3M | SEC |
| Q4 2025 | Feb 11, 2026 | $0.10 | $0.08 | −17.86% | $128.8M | SEC |
| Q3 2025 | Nov 12, 2025 | $0.09 | $0.08 | −15.34% | $126.0M | SEC |
| Q2 2025 | Aug 14, 2025 | $0.08 | $0.08 | +3.76% | $113.3M | SEC |
| Q1 2025 | May 14, 2025 | $0.05 | $0.07 | +33.33% | $107.5M | SEC |
| Q4 2024 | Feb 13, 2025 | $0.07 | $0.08 | +16.45% | $109.0M | SEC |
| Q3 2024 | Nov 6, 2024 | $0.07 | −$0.99 | −1425.30% | $106.9M | SEC |
| Q2 2024 | Aug 15, 2024 | $0.04 | −$0.12 | −430.58% | $95.7M | SEC |
| Q1 2024 | May 23, 2024 | $0.02 | −$0.36 | −1587.60% | $89.6M | SEC |
| Q4 2023 | Feb 15, 2024 | $0.03 | −$0.08 | −350.00% | $93.0M | SEC |
| Q3 2023 | Nov 14, 2023 | $0.03 | $0.03 | +17.19% | $84.2M | SEC |
| Q2 2023 | Aug 8, 2023 | $0.02 | −$0.17 | −1218.42% | $76.7M | SEC |
| Q1 2023 | May 10, 2023 | $0.01 | −$0.21 | −2758.23% | $71.2M | SEC |
| Q4 2022 | Feb 15, 2023 | $0.05 | $0.04 | −23.81% | $74.0M | SEC |
| Q3 2022 | Nov 17, 2022 | $0.01 | $0.13 | +2500.00% | $71.7M | — |
| Q2 2022 | Aug 11, 2022 | $0.01 | $0.17 | +1150.00% | $62.6M | — |
| Q1 2022 | May 12, 2022 | $0.01 | $0.27 | +2060.00% | $62.4M | — |
| Q4 2021 | Feb 16, 2022 | $0.02 | $0.25 | +1328.57% | $67.9M | — |
| Q3 2021 | Nov 10, 2021 | $0.01 | $0.08 | +1094.03% | $65.9M | — |
Quarterly revenue
Frequently asked questions
When did Cellebrite DI (CLBT) last report earnings?
Cellebrite DI last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did CLBT beat earnings estimates?
No. Cellebrite DI reported EPS of $0.02 for Q2 2026 against a $0.06 estimate — a 66.33% miss.
How much revenue did CLBT report last quarter?
Cellebrite DI reported $131.1M in revenue for Q2 2026, against a consensus estimate of $131.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.